Early COVID-Related pandemic impacts and subsequent opioid outcomes among persons receiving medication for opioid use disorder: a secondary data analysis of a Type-3 hybrid trial.
Tim JanssenBryan R GarnerJulia YermashKimberly R YapSara J BeckerPublished in: Addiction science & clinical practice (2023)
Mitigating the effect of the pandemic on patients' interpersonal relationships and employment, and promoting greater infection control in opioid treatment programs, could be protective against negative opioid-related outcomes. Trial registration The present study describes secondary data analysis on a previously registered clinical trial: clinicaltrials.gov/ct2/show/NCT03931174.
Keyphrases
- data analysis
- coronavirus disease
- sars cov
- clinical trial
- chronic pain
- pain management
- phase ii
- study protocol
- phase iii
- end stage renal disease
- chronic kidney disease
- ejection fraction
- newly diagnosed
- open label
- healthcare
- computed tomography
- public health
- type diabetes
- prognostic factors
- randomized controlled trial
- image quality
- positron emission tomography
- magnetic resonance imaging
- magnetic resonance
- adipose tissue
- metabolic syndrome
- contrast enhanced
- patient reported outcomes
- skeletal muscle